Literature DB >> 23737218

The sympathetic nervous system in chronic kidney disease.

Sebastian Ewen1, Christian Ukena, Dominik Linz, Roland E Schmieder, Michael Böhm, Felix Mahfoud.   

Abstract

Accumulating evidence has shown that the sympathetic nervous system plays an important role in the pathophysiology and progression of several chronic disorders, e.g., arterial hypertension, cardiac arrhythmias, heart failure, and in particular chronic kidney disease (CKD). Experimental and clinical studies provide evidence that sympathetic inhibition using either sympatholytic pharmacotherapy or catheter-based renal denervation has beneficial effects in patients with CKD. Randomized clinical trials are needed to characterize the underlying pathophysiological mechanisms, and systematically evaluate the therapeutic effects of sympathetic inhibition in this high-risk patient population. In this review current knowledge of the role of the sympathetic nervous system in the development and progression of CKD will be summarized, and novel treatment options targeting sympathetic nervous system activity will be discussed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23737218     DOI: 10.1007/s11906-013-0365-0

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  68 in total

Review 1.  Neurohormonal regulation of the sympathetic nervous system: new insights into central mechanisms of action.

Authors:  Scott H Carlson; J Michael Wyss
Journal:  Curr Hypertens Rep       Date:  2008-06       Impact factor: 5.369

2.  A limited renal injury may cause a permanent form of neurogenic hypertension.

Authors:  S Ye; M Gamburd; P Mozayeni; M Koss; V M Campese
Journal:  Am J Hypertens       Date:  1998-06       Impact factor: 2.689

3.  Sympathetic nerve traffic and asymmetric dimethylarginine in chronic kidney disease.

Authors:  Guido Grassi; Gino Seravalle; Lorenzo Ghiadoni; Giovanni Tripepi; Rosa Maria Bruno; Giuseppe Mancia; Carmine Zoccali
Journal:  Clin J Am Soc Nephrol       Date:  2011-09-22       Impact factor: 8.237

4.  Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure.

Authors:  G Ligtenberg; P J Blankestijn; P L Oey; I H Klein; L T Dijkhorst-Oei; F Boomsma; G H Wieneke; A C van Huffelen; H A Koomans
Journal:  N Engl J Med       Date:  1999-04-29       Impact factor: 91.245

5.  Rostral ventrolateral medulla : A source of sympathetic activation in rats subjected to long-term treatment with L-NAME.

Authors:  C T Bergamaschi; R R Campos; O U Lopes
Journal:  Hypertension       Date:  1999-10       Impact factor: 10.190

6.  Aliskiren reduces sympathetic nerve activity and blood pressure in chronic kidney disease patients.

Authors:  Laima Siddiqi; P Liam Oey; Peter J Blankestijn
Journal:  Nephrol Dial Transplant       Date:  2011-04-05       Impact factor: 5.992

7.  Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity.

Authors:  Shaohua Ye; Huiqin Zhong; Vijay Yanamadala; Vito M Campese
Journal:  Am J Hypertens       Date:  2002-08       Impact factor: 2.689

8.  Vascular and renal hemodynamic changes after renal denervation.

Authors:  Christian Ott; Rolf Janka; Axel Schmid; Stephanie Titze; Tilmann Ditting; Paul A Sobotka; Roland Veelken; Michael Uder; Roland E Schmieder
Journal:  Clin J Am Soc Nephrol       Date:  2013-04-04       Impact factor: 8.237

Review 9.  Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis.

Authors:  Bakhtawar K Mahmoodi; Kunihiro Matsushita; Mark Woodward; Peter J Blankestijn; Massimo Cirillo; Takayoshi Ohkubo; Peter Rossing; Mark J Sarnak; Bénédicte Stengel; Kazumasa Yamagishi; Kentaro Yamashita; Luxia Zhang; Josef Coresh; Paul E de Jong; Brad C Astor
Journal:  Lancet       Date:  2012-09-24       Impact factor: 79.321

10.  Renal denervation in a hypertensive patient with end-stage renal disease and small arteries: a direction for future research.

Authors:  Christian Ott; Axel Schmid; Tilmann Ditting; Paul A Sobotka; Roland Veelken; Michael Uder; Roland E Schmieder
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-10-03       Impact factor: 3.738

View more
  10 in total

Review 1.  The acute cardiorenal syndrome: burden and mechanisms of disease.

Authors:  Petra Nijst; Wilfried Mullens
Journal:  Curr Heart Fail Rep       Date:  2014-12

2.  Subcutaneous nerve activity and mechanisms of sudden death in a rat model of chronic kidney disease.

Authors:  Ye Zhao; Neal X Chen; Jonathan T Shirazi; Changyu Shen; Shien-Fong Lin; Michael C Fishbein; Sharon M Moe; Peng-Sheng Chen
Journal:  Heart Rhythm       Date:  2015-12-29       Impact factor: 6.343

3.  Application in Hypertension of Renal Sympathetic Denervation - A Review.

Authors:  Dominik Linz; Felix Mahfoud; Sebastian Ewen; Stephan H Schirmer; Jan Reil; Christian Ukena; Michael Böhm
Journal:  Interv Cardiol       Date:  2013-08

Review 4.  Autonomic cardiovascular alterations as therapeutic targets in chronic kidney disease.

Authors:  Gino Seravalle; Fosca Quarti-Trevano; Jennifer Vanoli; Chiara Lovati; Guido Grassi
Journal:  Clin Auton Res       Date:  2021-02-19       Impact factor: 4.435

5.  Renal denervation suppresses atrial fibrillation in a model of renal impairment.

Authors:  Zhuo Liang; Xiang-min Shi; Li-feng Liu; Xin-pei Chen; Zhao-liang Shan; Kun Lin; Jian Li; Fu-kun Chen; Yan-guang Li; Hong-Yang Guo; Yu-tang Wang
Journal:  PLoS One       Date:  2015-04-17       Impact factor: 3.240

6.  Establishment of a model of renal impairment with mild renal insufficiency associated with atrial fibrillation in canines.

Authors:  Zhuo Liang; Li-Feng Liu; Xin-Pei Chen; Xiang-Min Shi; Hong-Yang Guo; Kun Lin; Jian-Ping Guo; Zhao-Liang Shan; Yu-Tang Wang
Journal:  PLoS One       Date:  2014-08-26       Impact factor: 3.240

7.  Cardiovascular Interactions between Fibroblast Growth Factor-23 and Angiotensin II.

Authors:  Min Pi; Ruisong Ye; Xiaobin Han; Benjamin Armstrong; Xue Liu; Yuanjian Chen; Yao Sun; L Darryl Quarles
Journal:  Sci Rep       Date:  2018-08-17       Impact factor: 4.379

8.  Introduction and validation of a new semi-automated method to determine sympathetic fiber density in target tissues.

Authors:  Dennis Bleck; Li Ma; Lkham Erdene-Bymbadoo; Ralph Brinks; Matthias Schneider; Li Tian; Georg Pongratz
Journal:  PLoS One       Date:  2019-05-29       Impact factor: 3.240

9.  Sympathetic activation by lower body negative pressure decreases kidney perfusion without inducing hypoxia in healthy humans.

Authors:  René van der Bel; Jasper Verbree; Oliver J Gurney-Champion; Matthias J P van Osch; Erik S G Stroes; Aart J Nederveen; C T Paul Krediet
Journal:  Clin Auton Res       Date:  2018-11-02       Impact factor: 4.435

10.  Evaluation of Renal-Hepatic Functional Indices and Blood Pressure Based on the Progress of Time in a Rat Model of Chronic Kidney Disease.

Authors:  Hassan Askari; Behjat Seifi; Mehri Kadkhodaee
Journal:  Nephrourol Mon       Date:  2016-04-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.